CytoSorbents (NASDAQ:CTSO) said the Israeli Ministry of Health approved national reimbursement for CytoSorb in certain cardiac surgery indications which is expected to take effect in 2023.
The company added that once the policy revision is completed, public hospitals are expected to receive reimbursement for CytoSorb for the particular applications.
The company noted that CytoSorb removes a variety of antithrombotic drugs and inflammatory mediators intraoperatively during cardiac surgery. CytoSorb is an extracorporeal blood purification method to reduce excess inflammatory mediators and elevated levels of bilirubin and myoglobin.